Literature DB >> 9790437

Serologic responses to recombinant Plasmodium vivax Duffy binding protein in a Colombian village.

P A Michon1, M Arevalo-Herrera, T Fraser, S Herrera, J H Adams.   

Abstract

The Plasmodium vivax Duffy binding protein (DBP) is essential during merozoite invasion into human erythrocytes. Because of its biological importance, the DBP is also seen to have potential use as a malaria blood-stage vaccine. We have used a soluble recombinant DBP (rDBP) containing the functional ligand domain to assess the natural immunogenicity of DBP in a low-endemic vivax malaria region. Human sera from adult residents from a Colombian village with unstable vivax malaria transmission reacted specifically with the rDBP as determined by ELISA. There was a significant positive correlation between increased antibody response (average, median, and percent positives) and age of patients, although the level of responses did vary considerably in their reactivity to the rDBP from negative to very high level within each age group. These data confirm previous findings on the serologic reactivity of the DBP in exposed populations and that immunologic boosting to the DBP occurs in malaria-endemic regions even with low-level transmission.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790437     DOI: 10.4269/ajtmh.1998.59.597

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  22 in total

1.  Antibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmission.

Authors:  Sedigheh Zakeri; Laleh Babaeekhou; Akram Abouie Mehrizi; Maryam Abbasi; Navid Dinparast Djadid
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

Review 2.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

3.  Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies.

Authors:  Francis B Ntumngia; Jesse Schloegel; Samantha J Barnes; Amy M McHenry; Sanjay Singh; Christopher L King; John H Adams
Journal:  Infect Immun       Date:  2012-01-03       Impact factor: 3.441

4.  Epitope-specific humoral immunity to Plasmodium vivax Duffy binding protein.

Authors:  Jia Xainli; Jennifer L Cole-Tobian; Moses Baisor; Will Kastens; Moses Bockarie; Syed Shams Yazdani; Chetan E Chitnis; John H Adams; Christopher L King
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

Review 5.  Red blood cell polymorphism and susceptibility to Plasmodium vivax.

Authors:  Peter A Zimmerman; Marcelo U Ferreira; Rosalind E Howes; Odile Mercereau-Puijalon
Journal:  Adv Parasitol       Date:  2013       Impact factor: 3.870

6.  Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies.

Authors:  Patchanee Chootong; Francis B Ntumngia; Kelley M VanBuskirk; Jia Xainli; Jennifer L Cole-Tobian; Christopher O Campbell; Tresa S Fraser; Christopher L King; John H Adams
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

7.  Genetic polymorphism of Plasmodium vivax Duffy Binding Protein in malarious areas in southeastern of Iran.

Authors:  Mehdi Nateghpour; Afsaneh Motevalli Haghi; Bahare Naderi; Zargham Sepehrizadeh
Journal:  J Parasit Dis       Date:  2017-07-20

8.  Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.

Authors:  Francis B Ntumngia; Samantha J Barnes; Amy M McHenry; Miriam T George; Jesse Schloegel; John H Adams
Journal:  Clin Vaccine Immunol       Date:  2014-06-25

9.  Duffy Blood Group System and the malaria adaptation process in humans.

Authors:  Gledson Barbosa de Carvalho; Glauber Barbosa de Carvalho
Journal:  Rev Bras Hematol Hemoter       Date:  2011

10.  Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques.

Authors:  A Moreno; I Caro-Aguilar; S S Yazdani; A R Shakri; S Lapp; E Strobert; H McClure; C E Chitnis; M R Galinski
Journal:  Vaccine       Date:  2008-06-23       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.